Dermatology Times is beginning to shape a guide to 2024's summer and early fall dermatologic conferences and meetings. What conferences are you planning to attend between July and September? Share with us below. ⬇️ https://lnkd.in/ggmSnFQG
Dermatology Times’ Post
More Relevant Posts
-
At #AAD2024, Melinda Gooderham, MSc, MD, FRCPC, presented late-breaking data on the long-term safety and efficacy of #delgocitinib for moderate to severe chronic hand eczema. As the lead author of DELTA 3, Gooderham spoke with Dermatology Times to emphasize the key findings of the trial and what dermatologists need to know. https://lnkd.in/gyz6sAga
Late-Breaking Data: Long-Term Safety and Efficacy of Delgocitinib Cream for Chronic Hand Eczema
dermatologytimes.com
To view or add a comment, sign in
-
I hope everyone is enjoying a positive start to the year. Dermatology and Therapy had a particularly busy 2023 with a record number of submissions, 187 publications and a record number of downloads. Our annual downloads surpassed 1.5 million. Why not read some of our highly anticipated invited review articles published in 2023: 🚦 JAK inhibitors are disease-modifying agents with efficacy in treating a spectrum of burdensome dermatologic conditions not without their own safety concerns. Here Shawn Kwatra and co-authors provide an overview of the timeline of FDA approval of JAK inhibitors in dermatology: https://bitly.ws/BnCs 💡 Our Editorial Board Member, Jennifer Hsiao, contributed a two-part collection exploring the emerging topical and systemic therapies as well as procedural, wound care dressing and devices being investigated for the management of #hidradenitissuppurativa: 1️⃣ Part 1: https://bitly.ws/3afVB 2️⃣ Part 2: https://bitly.ws/3afVM 💊 A more extensive understanding of #atopicdermatitis etiology and pathogenesis has allowed the development of several topical and systemic novel therapy options. This latest review presents the latest systemic agents currently under investigation: https://bitly.ws/3afWZ 🔊 A very recently published review offers an updated reference for #rosacea management by covering the latest developments in both topical and systemic treatments, including data from newly approved therapies, updates to current treatment modalities and ongoing clinical trials: https://bitly.ws/3afYf 🎤 What is the relationship of the skin microbiome in #acne and implications for treatment ❓ Read our most recent review here: https://bitly.ws/3ag4U 💗 We are excited by the continued advanced in treatment in dermatology. Keep checking in for our newest reviews and ideas for 2024 including in #epidermolysisbullosa, the rapidly growing field of #psychodermatology, #woundhealing, #alopecia and more..
To view or add a comment, sign in
-
🗓 WEEKLY ROUNDUP: Review our recap of dermatology news coverage from the past week, including bimekizumab's 2-year efficacy data in hidradenitis suppurativa, new long-term results for ESK-001 in psoriasis, and more. https://lnkd.in/geCiGshD
The Weekly Roundup: September 30-October 4
dermatologytimes.com
To view or add a comment, sign in
-
In a recent interview with Dermatology Times, Raj Chovatiya, MD, PhD, and Lawrence Eichenfield, MD, shared their insights and key treatment pearls for optimal atopic dermatitis care across all ages: 1. Understanding the clinical presentations in adult versus pediatric patients is crucial for making an accurate diagnosis and then developing an appropriate treatment regimen. 2. All around, standard first-line treatment for atopic dermatitis includes having good bathing practices, moisturising after bathing, and choosing an ideal ointment or lotion for each patient. 3. It’s best to use topical corticosteroids or topical non-steroidal agents to get the condition under control and then use non-steroidal topical agents to keep it under control. 4. Promising non-steroidals topicals include ruxolitinib and roflumilast. Read the full article here: https://bit.ly/3tBZn7S
To view or add a comment, sign in
-
🗓️ MONTH IN REVIEW: Explore our recap of the top stories in dermatology from the month of August, including the approval of denileukin diftitox-cxdl for CTCL, phase 3 data for izokibep in hidradenitis suppurativa, and more. 🖇 Review clearances and approvals, big studies and data, market and pharma news, and strides for skin health equity: https://lnkd.in/gJeGNMYC
Dermatology Times August 2024 Recap
dermatologytimes.com
To view or add a comment, sign in
-
In recognition of Psoriasis Awareness Month, it’s important to highlight the ongoing efforts to advance dermatological research for the millions of people affected by psoriasis worldwide. With approximately 125 million people living with this chronic condition, continuous innovation in research is vital. MAC has been an active participant in advancing this research, having conducted 8 psoriasis studies over the past 5 years, and more than 20 dermatology studies overall. Dr Aliya Asher, Chief Medical Officer at MAC Clinical Research has extensive experience in dermatology. Dr Asher has acted as Chief Investigator, PI, and Sub-I on several dermatology trials conducted at MAC, including First-in-Human (FIH) through later phases, for treatments for atopic dermatitis, psoriasis, and psoriatic arthritis. Find out more about our experience in dermatology: https://lnkd.in/dtSJn_vc If you’d like to speak to us about your study requirements, contact us here:https://lnkd.in/dfATZDen #PsoriasisAwareness #MACClinicalResearch #PsoriasisResearch #ClinicalTrials #DrugDiscovery #HopeForPsoriasis
To view or add a comment, sign in
-
Dermatologist l Researcher l Educator Assistant Clinical Professor of Dermatology Yale University, Associate Director of Clinical Trials CCD Research, Partner at Central CT Dermatology
If you’re a dermatologist, it’s been quite the year of innovation! Join us in this frontline #psoriasis forum as we review the current landscape for the treatment of plaque psoriasis and discuss what matters most to the practicing clinician! Dermatology Times
Frontline Forum Sneak Peek: Expert Insights on Psoriasis Treatment Guidelines
dermatologytimes.com
To view or add a comment, sign in
-
📃Scientific paper: Topical proactive therapy in dermatology. A scoping review Abstract: The term ‘proactive therapy’ refers to a long-term management of clinically intact skin in previously disease-affected areas. This method was initially implemented in atopic dermatitis to maintain the remission and decrease the risk of exacerbations. Proactive therapy aims to limit the need for reactive treatment and improve the patients’ quality of life. A proactive approach is likely to be adopted for other relapsing and inflammatory skin conditions in the future. This scoping review aims to identify dermatological conditions to be treated with the proactive approach, evaluate the available evidence for its efficacy and safety, as well as highlight the research gaps. Continued on ES/IODE ➡️ https://etcse.fr/ZU1 ------- If you find this interesting, feel free to follow, comment and share. We need your help to enhance our visibility, so that our platform continues to serve you.
Topical proactive therapy in dermatology. A scoping review
ethicseido.com
To view or add a comment, sign in
-
The July Case-Based Peer Perspective supplement of Dermatology Times includes a collection of thought-provoking discussions and strategies surrounding how to address difficult #atopicdermatitis cases. Review our top highlights below. https://lnkd.in/g7Jbs2qW
Discovering Dermatology Times: July 2024 Challenging Atopic Dermatitis Cases Supplement
dermatologytimes.com
To view or add a comment, sign in
-
American Academy of Dermatology's Latest Guidelines for Acne Vulgaris Management 31 Jan, 2024 • The American Academy of Dermatology has recently released 18 robust evidence-based recommendations and 5 good practice statements for the management of acne vulgaris. KEY POINTS 介 Home • Strong recommendations are made for benzoyl peroxide, topical retinoids, topical antibiotics, and oral doxycycline. • Oral isotretinoin is strongly recommended for acne that is severe, causing psychosocial burden or scarring, or failing standard oral or topical therapy. • Conditional recommendations are made for topical clascoterone, salicylic acid, and azelaic acid, as well as for oral minocycline, sarecycline, combined oral contraceptive pills, and spironolactone. Combining topical therapies with multiple mechanisms of action, limiting systemic antibiotic use, combining systemic antibiotics with topical therapies, and adding intralesional corticosteroid injections for larger acne lesions are recommended as good practice statements. Source : JAAD https://lnkd.in/dMQNfRsJ
To view or add a comment, sign in
28,401 followers